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Treatment planning is time-consuming and the outcome depends on the person 
performing the optimization. A system that automates treatment planning could 
potentially reduce the manual time required for optimization and could also pro-
vide a method to reduce the variation between persons performing radiation dose 
planning (dosimetrist) and potentially improve the overall plan quality. This study 
evaluates the performance of the Auto-Planning module that has recently become 
clinically available in the Pinnacle3 radiation therapy treatment planning system. 
Twenty-six clinically delivered head and neck treatment plans were reoptimized 
with the Auto-Planning module. Comparison of the two types of treatment plans 
were performed using DVH metrics and a blinded clinical evaluation by two senior 
radiation oncologists using a scale from one to six. Both evaluations investigated 
dose coverage of target and dose to healthy tissues. Auto-Planning was able to 
produce clinically acceptable treatment plans in all 26 cases. Target coverages in 
the two types of plans were similar, but automatically generated plans had less 
irradiation of healthy tissue. In 94% of the evaluations, the autoplans scored at 
least as high as the previously delivered clinical plans. For all patients, the Auto-
Planning tool produced clinically acceptable head and neck treatment plans without 
any manual intervention, except for the initial target and OAR delineations. The 
main benefit of the method is the likely improvement in the overall treatment qual-
ity since consistent, high-quality plans are generated which even can be further 
optimized, if necessary. This makes it possible for the dosimetrist to focus more 
time on difficult dose planning goals and to spend less time on the more tedious 
parts of the planning process.
PACS number: 87.55.de
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I. INTRODUCTION
A number of uncertainties and variations are present in radiotherapy such as absolute dose 
precision,(1) delivery precision,(2,3,4,5) precision of calculated dose distributions,(6,7,8,9) and 
radioresponsiveness of the specific tumor and normal tissues.(10,11,12,13,14,15) Two of the largest 
variations within radiotherapy are the heterogeneity in target definition(16,17,18)  and the varia-
tion among treatment plans for a given geometry both intra- and interinstitutional.(19,20) Most 
treatment plans are likely to have sufficient dose coverage of the delineated targets, but large 
variations in dose to healthy tissues occur.
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The dose distribution depends on the dose objective defined by the dosimetrist, typically 
in accordance with institution-specific guidelines. However, even guidelines do not ensure an 
optimal dose distribution for the specific anatomy, since the lower achievable dose limit to an 
OAR for a specific patient is unknown. This is the reason why treatment plans are optimized 
for the individual patient by trained dosimetrists. Moreover, the treatment optimization is 
labor-intensive work with a very large solution space, which makes it difficult to ensure that the 
clinical treatment plan is the optimal plan. Therefore, there is a need to automate the treatment 
planning optimization procedure both to reduce the amount of time spent on the optimization 
and, more importantly, to reduce the interdosimetrist variation.
If an automatically generated treatment plan of high clinical quality is available prior to 
manual optimization, it could serve as a quality reference and starting point for the specific 
treatment and thereby ensure a certain minimum quality. Furthermore, the automatic plans could 
potentially be a time-saving tool during the treatment optimization, which would reduce one of 
the most tedious steps in the process. Sharing the optimization parameters between institutions 
could also provide a method to share knowledge and standardize plan quality.
Previous documented solutions with somewhat different approaches have shown the potential 
of automation of the planning process.(21,22,23,24,25) The current study validates the performance 
of a prototype version of the Auto-Planning module which recently has been productized for 
clinical use in the Pinnacle3 treatment planning system from Philips Healthcare (Fitchburg, WI). 
 
II. MATERIALS AND METHODS
The Auto-Planning software was evaluated by replanning 26 previously delivered clinical 
head and neck IMRT treatment plans of the oropharynx. The plans were delivered over the 
12 months prior to the study. The plans were created in accordance with the Danish Head And 
Neck Cancer Groups guidelines (DAHANCA - Version 2004), and each dose plan included 
three dose levels of 50 Gy, 60 Gy, and 66 or 68 Gy in 33 treatment fractions with a simultane-
ous integrated boost technique.
In the Auto-Planning software, a template of configurable parameters known as a Technique 
(details in Appendix A) can be defined for each treatment protocol. The Techniques include 
definition of beam parameters and planning goals. The Auto-Planning module uses the Technique 
definition to iteratively adjust IMRT planning parameters to best meet the planning goals. The 
Technique was defined according to local standards, including prioritization between target 
coverage and dose to organs at risk. The Technique definition was based on five additional 
pilot patients independent of the 26 study patients.
Each of the 26 treatment plans were replanned with Auto-Planning without knowledge of 
the clinically delivered treatment plans and without any dosimetrist postoptimization of the 
treatment plans. The only input to the replanning was the delineations of planning target and 
organs at risk and the positioning of the isocenter.
Quantitative dosimetric evaluation of the performance of the treatment plans was performed 
on dose volume histograms (DVH) extracted from the planning system. CT scans had a slice 
thickness of 3 mm and in plane voxel size of 1 mm × 1 mm. The dose plans were calculated 
using the Pinnacle3 collapsed cone algorithm with a dose grid resolution of 3 mm. Specific 
DVH values, as well as the overall shape of the DVH, was compared using average DVHs of 
the two types of treatment plans.
The average DVH was calculated for each type of treatment plan as the average of the 
patient-specific DVH values at each dose level. To specify dose regions for which statistically 
significant differences exist, a probability curve as in Bertelsen et al.(26) was calculated. In short, 
the probability curve is a Wilcoxon matched-pair, signed-rank test performed at each dose level. 
Individual values of the curve are not strict statistical tests since the test is performed multiple 
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times and on values that are not mutually independent. The probability curve is, therefore, 
primarily a tool that indicates regions for which the average DVHs deviate significantly.
The DVH analysis was performed for all target volumes, as well as for parotid gland, 
submandibular gland, and spinal cord. To evaluate dose to other normal structures than the 
delineated, a DVH evaluation of all healthy tissues outside the PTV was performed. In con-
trast to the previous DVH evaluations, this evaluation was performed in absolute volume to 
compensate for a difference of the CT scanned volume of each patient (relative values would 
depend on the scanned volume).
The dosimetric evaluation was extended with a blinded clinical evaluation of the treatment 
plans. Two senior head and neck radiation oncologist independently scored the treatment plans 
on a categorical scale from 1 to 6 (1 = bad and 6 = good). The scoring was performed for target 
coverage, sparing of healthy tissues, and an overall assessment of the treatment plan. Finally, 
based on the clinical evaluation, the radiation oncologists selected the plan they would favor for 
clinical treatment. The radiation oncologist had access to all clinical information and diagnostic 
scans. The evaluation was performed similar to the clinical procedure used for evaluation of 
two different proposals for a given clinical treatment. All information related to the production 
of the plans was blinded and the treatment plans were presented for evaluation in random order.
All statistical tests were made by Wilcoxon matched-pair, signed-rank test using a signifi-
cance level of 5%.
 
III. RESULTS 
Average DVH comparison between automatic and the clinical delivered plans for the targets 
is shown in Fig. 1. In accordance with ICRU 83,(27) PTV50 includes PTV60 and PTV 66/68 
causing the long tail towards high doses. Likewise, PTV60 contains PTV66/68. For PTV50, 
the autoplans had a small, but statistically significant, lower dose than the clinical plans below 
95% of the 50 Gy and also above ~ 110% of the 50 Gy.
The PTV60 had a similar pattern as the PTV50 below ~ 92% of 60 Gy. A slightly higher aver-
age dose for the autoplans was also observed, while no differences were seen for higher doses. 
For the highest dose level, PTV66/68, the trend of a small, but statistical lower, dose below 
95% of prescribed dose was observed for the autoplans, while no other differences were found.
The observations from Fig. 1 are reflected in Table 1 which shows selected DVH parameters. 
The difference in steepness of the DVH for PTV50 is statistically significant, with the automatic 
plans having the steeper slope. Also, the minimum dose was different for the two types of plans, 
with the clinical plans having a slightly higher minimum dose. Nevertheless, for both types of 
plans, the average DVH covers the PTV50 with the 95% isodose lines for at least 98.5% of the 
target which meets the ICRU 83 recommendation,(27) as well as the 2013 DAHANCA guidelines 
and QA evaluations.(28) For PTV60, the only statistically significant differences observed were 
Fig. 1. Mean DVHs of the target volumes for the clinical (red) and auto (blue) plans normalized to the prescribed doses 
for each PTV. P-value curves are shown in gray.
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a slightly higher dose level for 
the automatic plans (Table 1). 
For the highest dose level, the 
automatic plans produce more 
conformal dose distributions 
(Conformity Index CI 95%), 
but slightly less maximum and 
minimum dose. 
Average DVH curves for the 
organs at risk (OAR) are shown 
in Fig. 2. For all the delineated 
organs, the average DVH doses 
from the autoplans are either 
less than or equal to those of 
the clinical plans. There are 
no dose ranges for which the 
autoplans generated statisti-
cally significant higher doses 
to the delineated OAR.
To evaluate dose to nonde-
lineated healthy tissues, Fig. 
2(f) shows the DVH difference 
for all tissues outside the PTV. 
The figure demonstrates the dif-
ference of the absolute volume 
irradiated above a specific dose 
level for the clinical plans minus 
the automatic plans. For all dose 
levels up to ~ 55 Gy, the dose 
levels outside the PTVs were 
lower for the automatic plans. 
Above ~ 55 Gy, the two types of 
plans were equal to each other.
To quantify the DVH differ-
ences and their variation, selected 
DVH metrics for the organs at 
risk are shown in Table 2. 
The overall result in Table 2 
is as stated above, that the 
OAR receives less dose using 
the automatic generated plans 
than the previously delivered 
plans. Part of the observed dose 
differences was related to inter-
dosimetrist variation. Figure 3 
shows an example of all pairs 
of DVH for ipsilateral parotid, 
which illustrates that the auto-
plans are confined to a narrower 
region than the manual plans.
The evaluations by the oncol-
o gists are shown in Table 3. Ta
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Except for Patient 16, the main finding is that the qualities of both types of plans are good. 
Patient 16 failed to meet the maximum dose goal to the spinal cord which has a very high clini-
cal priority, but for the other targets and organ delineations, the plan was evaluated as good. 
In terms of target coverage, the scores were not statistically significantly different between the 
two types of plans for any of the two observers; however, a p-value of 0.079 for one observer 
could indicate a preference for the clinical plans in term of target coverage.
The clinical evaluation of the dose to the OARs was clearly in favor of the autoplans for 
both observers, which is consistent with the dosimetric observations in Fig. 2 and Table 2. For 
the overall evaluation of the plans, one observer is clearly in favor of the autoplans, while the 
other observer showed no statistically significant differences. In 94% of the cases, the overall 
score for the autoplans were as good as, or better than, the clinical plans. The last column of 
Table 3 shows the preferred treatment plans by the clinicians. The column reflects the overall 
plan score, and shows that the observer with a difference in the overall evaluation only selected 
automatic plans while the observer who did not find a significant overall difference selected 
the automatic plans and the clinical plans evenly.   
 
Fig. 2. Mean DVHs of the OAR for the clinical (red) and auto (blue) plans. P-value curves are shown in gray. Figure 
2(f) show the average absolute volume difference in cm3 between the DVHs for the healthy tissue for the clinical minus 
the autoplans.
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Table 2. Mean values for doses to organs at risk. Uncertainties of all values are reported as 1 SD. Statistically significant 
differences are shown in bold.
  Clinical Auto p
Spinal Cord
 Mean (Gy) 26.03±5.13 21.13±4.55 <0.001
 Max (Gy) 42.35±1.56 39.60±3.62 <0.001
 D2% (Gy) 40.50±1.45 36.23±3.60 <0.001
 V35Gy 0.46±0.19 0.09±0.10 <0.001
Submandibular Contralateral
 Mean (Gy) 47.33±7.66 40.41±6.87 <0.001
 V30Gy 0.94±0.20 0.79±0.19 <0.001
 V39Gy 0.85±0.25 0.56±0.21 <0.001
 V60Gy 0.08±0.16 0.05±0.12 0.074
Submandibular Ipsilateral
 Mean (Gy) 57.62±6.78 54.54±9.18 0.001
 V30Gy 0.99±0.03 0.92±0.11 <0.001
 V39Gy 0.94±0.12 0.84±0.20 <0.001
 V60Gy 0.53±0.33 0.49±0.30 0.072
Parotid  Contralateral
 Mean (Gy) 30.48±5.71 26.55±4.02 <0.001
 V5Gy 0.96±0.07 0.94±0.08 0.033
 V26Gy 0.60±0.19 0.46±0.11 <0.001
 V35Gy 0.42±0.16 0.30±0.12 <0.001
Parotid  Ipsilateral
 Mean (Gy) 35.54±6.84 29.73±5.57 <0.001
 V5Gy 0.96±0.09 0.94±0.12 0.007
 V26Gy 0.71±0.19 0.51±0.11 <0.001
 V35Gy 0.52±0.16 0.37±0.12 <0.001
Fig. 3. Pairs of DVH for ipsilateral parotid, illustrating the less variation of autoplans.
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IV. DISCUSSION
For all 26 patients it was possible to produce automatic plans of high plan quality. Small differ-
ences in the PTV dose coverage but a significant reduction in dose to OAR between automatic 
plans and clinical plans indicate that the Technique parameters used in the current study are 
biased towards normal tissue sparing relative to the clinical practice. It is likely that another 
set of Technique parameters could be determined which would focus more on dose coverage. 
In addition, in the clinical release of the Auto-Planning software, modifications have been 
made to enhance the priority of maximum dose constraints to OAR such as the cord, a need 
highlighted by the physicians during plan evaluation. No postoptimization of the plans was 
performed in the study to make a pure validation of the Auto-Planning software. If needed or 
requested, in a clinical situation automatic optimized plans could be further optimized just as 
any manually created plan since the automatic plans are delivered in exactly the same format 
as manually created plans. Thus, the automatic plans can either be a high quality starting point 
for further manual optimization or an attempt to produce plans of clinical quality without 
further user intervention.
It is likely that the reduced dose to normal tissue of the sizes seen in Fig. 2 could be of clini-
cal impact for the patients, while the small difference in tumor coverage will almost certainly 
have no clinical impact. However, without no definitive answer to which plan is the better in 
Table 3. Clinical evaluation of the auto and clinical plans on a score from one to six (1 = bad – 6 = good). The observers 
scores are shown in each columns separated by a slash. At the lower part of the table, mean values for both the individual 
observers and a combined score is shown together with a test of statistically significant differences between the score 
for auto and clinical plans. For Patient 16 please see note in text. Statistically significant differences are shown in bold.
 Target Coverage Organs at Risk Overall Quality Selected Plan
 Patient Clinical Auto Clinical Auto Clinical Auto Clin=0;Auto=1
 1 5/6 6/5 4/5 5/6 5/5 6/5 1/0
 2 4/5 5/5 6/4 5/6 5/4 5/6 1/1
 3 6/5 6/6 5/4 6/6 5/5 6/6 1/1
 4 6/6 6/6 5/5 6/6 5/6 6/6 1/1
 5 6/6 6/5 5/5 6/6 5/6 6/6 1/0
 6 6/5 6/6 4/5 5/6 5/5 6/6 1/1
 7 6/5 6/6 5/5 6/6 5/5 6/6 NA/1
 8 6/6 6/5 5/5 6/6 6/5 6/5 1/0
 9 5/6 6/5 5/5 5/6 5/6 6/6 1/0
 10 6/5 5/6 4/3 6/5 4/3 5/5 1/1
 11 6/6 6/6 4/5 6/6 5/6 6/6 1/1
 12 6/6 6/6 4/5 6/6 5/6 6/6 1/1
 13 6/6 6/5 4/5 6/6 5/6 6/6 1/0
 14 5/6 5/5 4/5 6/6 5/6 6/6 1/0
 15 6/6 6/6 4/5 6/6 5/6 6/6 1/1
 16 6/6 5/5 4/6 6/1 5/6 6/1 1/0
 17 5/5 5/6 4/4 5/6 NA/4 NA/6 1/1
 18 6/6 5/4 4/5 5/5 4/6 5/5 1/0
 19 5/6 6/6 4/6 6/6 5/6 6/6 1/0
 20 5/6 5/6 4/6 6/6 5/6 6/6 1/1
 21 5/6 6/5 4/6 6/6 5/6 5/6 1/0
 22 6/6 6/6 5/5 6/6 5/6 6/6 1/1
 23 6/6 6/5 5/5 6/6 5/5 6/5 1/0
 24 6/4 5/3 5/5 6/6 6/4 6/4 1/0
 25 6/6 6/5 5/5 6/6 5/6 6/6 1/0
 26 6/NA 6/NA 4/NA 6/NA 5/NA 6/NA 1/NA
 Mean Observ 5.65/5.68 5.69/5.36 4.46/4.96 5.77/5.72 5.00/5.40 5.84/5.52 1.00/0.48
 Mean Total 5.67 5.53 4.71 5.75 5.20 5.68 0.74
 P Observ  0.739/0.074 <0.001/0.001 <0.001/0.285
 P total 0.194 <0.001 <0.001
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terms of tumor control and sparing of normal tissue (e.g., based on large randomized trials), 
the evaluation of the clinical quality of the plans will be somewhat subjective and depend upon 
individual views of the oncologist judging the plans. In the current study there are indications 
that the two oncologists have slight differences in their priorities. As stated in the results, both 
oncologists scores the OAR irradiation significantly better for the automatic plans compared 
to the manual plans, while none of the oncologists found statistically significant differences 
between the automatic and manual plans in terms of target coverage; although a p-value of 
.074 for one of the oncologist indicates a favor of target coverage from the manual plans. These 
differences are also reflected in selection of treatment plan in which one oncologist only select 
the automatic plans while the other select an even mixture of automatic and manual plans. 
However, independent of the interoncologist variations, it is interesting to observe that in 94% 
of the cases (all except for one) the overall score given to the automatic plan is at least as high 
as the score for the manual plan, indicating that most of the plans could be used clinically 
without any user intervention. Only for one plan, one of the oncologists scored the automatic 
plan lower than the manual plan due to a violation of the maximum dose constraint of the 
spinal cord. With slight manual effort, this single treatment plan was later optimized to have 
an acceptable maximum spinal cord dose.
A prerequisite to achieve high-quality automatic plans compared to manually created plans is 
obviously a sound optimization and tuning algorithm (the Auto-Planning engine). However, the 
quality of the manual plans is obviously also of importance in comparison with the automatic 
plans (poor quality manual plan would favor automatic plans). At the time the manually created 
plans were made, all clinical head and neck treatment plans in the department were created 
using IMRT; thus the department was experienced in creating “high quality” plans manually. 
As a result, given the significant experience with IMRT in the department, the interdosimetrist 
variation should be limited. Nevertheless, as seen in Fig. 3, there is quite a variation in manually 
optimized plans, a variation which is less for the automatic optimization. It therefore seems likely 
that one of the advantages of automatic plans is a reduction of the interdosimetrist variation 
which is present even within departments that use IMRT extensively. The reason of the inter-
dosimetrist variation is related both to limited time to create the plan and to lack of knowledge 
of how much the plan in reality can be optimized. For a manually created plan, it is difficult to 
know the extent an OAR can be spared prior to actual plan optimization. Therefore, objectives 
for organs at risk are typically set relatively loose initially, in order to ensure dose coverage of 
the target. Having obtained dose coverage of target, the next step is to reduce the dose to organs 
at risk as much as possible. In a busy clinic, it can be hard to ensure that all constraints on organs 
at risk have been tightened as much as possible. This issue could be reduced significantly if an 
initial “high quality” plan — e.g., an automatic generated plan — were available such that the 
dosimetrist could focus on fine tuning of the treatment plan. 
Another potential benefit of Auto-Planning could be a simple method to exchange planning 
knowledge and procedures between institutions since the Technique configuration of the Auto-
Planning software can easily be shared between institutions. This could help institutions with, 
for example, limited resources to quickly create IMRT or VMAT plans with similar quality as 
in more advanced institutions.
Most previous work on automating the planning process has built on knowledge of previously 
treated patients. One approach of extracting information from previously treated patients is 
utilizing the overlap volume histogram method, which measures the position of an OAR rela-
tive to the target.(19,29,30,31) Knowledge of overlap volume histograms from previously treated 
patients can be used to predict the likely achievable irradiation level of specific OARs. A few 
published solutions on automating the planning process have been documented,(21,22,23,24,25) 
and all build on the Pinnacle3 planning system. The published systems did show the feasibility 
of automating the planning process. However, in terms of flexibility, it could be a potential 
issue that “knowledge based” approaches require a database of “high” quality plans for each 
protocol. Changes to planning techniques, prescriptions, OAR sparing goals, and contouring 
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style could, if not implemented in a very smart way, require a new “high” quality database. Such 
a change could be quite labor-intensive to implement clinically, and might not be as flexible 
to interchange between institutions. This issue might be addressed within “knowledge based” 
algorithms, but is not present in the Auto-Planning solution evaluated in this study since it only 
relies on a small set of Technique parameters.  
Finally, it should be mentioned that plan comparison studies are inherently difficult to perform 
since development of the treatment planning skill is continually ongoing within any department 
in order to optimize the treatments plans. Thus, if the current study was repeated, the results 
might be different since our dose planning team has learned new ways to improve the quality 
based on the results of this study. Similar statements could be made about the configuration 
of the automatic system. However, this does not change the fact that the current comparison 
between treatment plans that have been delivered clinically and the automatic treatment plans 
did show the autoplans to be superior at that time. Thus, the impact of Auto-Planning seems 
likely to be a tool to increase the overall quality of dose planning, rather than a tool that could 
remove the need of manual optimization.
 
V. CONCLUSIONS 
Comparison of autoplans and previous delivered clinical plans showed only small dosimetric 
differences in target coverage, but significant reduction in dose to OAR for the autoplans. The 
blinded clinical evaluation of the plans showed that, for 94% of the evaluations, the autoplans 
were similar to or better than the clinical plans. Auto-Planning software will, therefore, be able 
to reduce the manual time spend per treatment plan since the most of the plans could potentially 
be used clinically without further optimization. Perhaps more importantly, Auto-Planning could 
be used as a high quality starting point for further plan optimization. This could increase the 
overall quality of the treatments and reduce the interobserver variation present in manually 
created treatment plans.
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APPENDICES 
Appendix A. Description of Auto-Planning.
This Auto-Planning module simplifies the planning process through the use of templates called 
Techniques, and automatic optimization tuning methods called the Auto-Planning engine (APE).
The user can define the following parameters in a Technique:
-  Derived regions of interest (ROIs) (e.g., PTV or expanded cord)
-  Placement of points of interest (POIs)
-  Prescriptions
-  Beam geometries, settings, and optimization options
-  Prioritized optimization goals
A single selection creates a new plan based on the Technique settings and runs the APE. 
The APE tuning method maps the prioritized optimization goals defined in the Technique to 
optimization objectives. Multiple optimization loops are performed that iteratively adjust the 
optimization parameters to meet the goals and further drive down organ at risk (OAR) sparing 
with minimal compromise to the target coverage. This is achieved by using objectives specific 
to driving down OAR dose to the point it significantly affects target coverage and separate 
objectives to achieve the desired goals. Target conformality is automatically controlled by 
a system-generated ring structure, and objectives and body dose is controlled by a system-
generated normal tissue structure and objectives. The objective dose and weight parameters 
are tuned using a proprietary method. Target uniformity is controlled by reducing hot and cold 
spots using system-generated control structures and objectives similar to the process defined 
in the study by Xhaferllari et al.(32)
The input to a Technique is clinical goals (e.g., maximum dose, mean dose, and DVH con-
strains), as well as the pertinent parameters listed above. Optimization of a Technique is an 
iterative process in which Auto-Planning is performed on test patients. If there are short-comings 
in the autoplan results, the optimization goals in the Technique are adjusted to account for them 
and saved. In the current work, the optimization of the Technique was performed on separate 
patients than those included in the study, and finalized before autoplanning was performed on 
any of the patients included in the current study.
